Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT.  However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]